 <h1>Soliris Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>eculizumab</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about eculizumab. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Soliris.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to eculizumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Meningococcal infections, which may rapidly become life-threatening or fatal if not recognized and treated early, have been reported in patients treated with eculizumab. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies. Immunize patients with a meningococcal vaccine at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection. Vaccination reduces, but does not eliminate, the risk of meningococcal infections. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected. Eculizumab is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS). Under the eculizumab REMS prescribers must enroll in the program. Enrollment in the eculizumab REMS program and additional information are available by telephone: 1-888-SOLIRIS (1-888-765-4747) or at solirisrems.com.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, eculizumab (the active ingredient contained in Soliris) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking eculizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>black, tarry stools</li>
<li>bladder pain</li>
<li>blindness</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>burning or stinging of the skin</li>
<li>burning, dry, or itching eyes</li>
<li>chest pain</li>
<li>chills</li>
<li>cough</li>
<li>cough producing mucus</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty breathing</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>joint pain or swelling</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>muscle ache, cramp, pain, or stiffness</li>
<li>nausea</li>
<li>nervousness</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>shivering</li>
<li>slow or fast heartbeat</li>
<li>sneezing</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stuffy or runny nose</li>
<li>sweating</li>
<li>swollen glands</li>
<li>tightness of the chest</li>
<li>trouble sleeping</li>
<li>troubled breathing with or without exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>General feeling of discomfort or illness</li>
<li>hoarseness</li>
<li>itching, pain, redness, swelling, tenderness, or warmth on the skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of eculizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bone pain</li>
<li>constipation</li>
<li>difficulty having a bowel movement</li>
<li>difficulty in moving</li>
<li>mouth or throat pain</li>
<li>pain in the arms or legs</li>
</ul><p>
<i>More common</i>
</p><ul>
<li>Bruise</li>
<li>hair loss or thinning of hair</li>
<li>lack or loss of strength</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to eculizumab: intravenous solution</i></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Meningococcal sepsis, aspergillus infection, arthritis bacterial, oral herpes, viral infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Meningococcal meningitis, Neisseria infection, sepsis, septic shock, fungal infection, Haemophilus influenza infection, abscess, cellulitis, influenza, cystitis, gingival infection, impetigo, tooth infection</p>
<p><b>Rare</b> (0.01% to 0.1%): Aspergillus infection, bacterial arthritis, impetigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis, bronchitis, dyspnea, cough, nasal congestion, pharyngolaryngeal pain, rhinorrhea, pneumonia</p>
<p><b>Uncommon</b> (0.1% to 1%): Lower respiratory tract infection, sinusitis, epistaxis, throat irritation<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (15%), arthralgia (17%)</p>
<p><b>Common</b> (1% to 10%): Myalgia, muscle spasms, bone pain, neck pain, pain in extremity</p>
<p><b>Uncommon</b> (0.1% to 1%): Trismus, joint swelling<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, vomiting, nausea, abdominal pain, constipation, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal infection, peritonitis, gastroesophageal reflux disease, abdominal distension, gingival pain</p>
<p><b>Rare</b> (0.01% to 0.1%): Gingivitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia, leukopenia, anemia, hemolysis</p>
<p><b>Uncommon</b> (0.1% to 1%): Coagulopathy, red blood cell agglutination, abnormal clotting factor, anemia, lymphopenia, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, hematocrit decreased, hemoglobin decreased, thrombocytopenia, lymphopenia</p>
<p><b>Rare</b> (0.01% to 0.1%): Hemolysis, abnormal clotting factor, red blood cell agglutination, coagulopathy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (33%), hypotension (17%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Palpitation, accelerated hypertension, hematoma, hot flush, vein disorder<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (41%)</p>
<p><b>Common</b> (1% to 10%): Dizziness, dysgeusia</p>
<p><b>Uncommon</b> (0.1% to 1%): Syncope, tremor, paresthesia<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reaction was headache (occurred mostly in the initial phase) and the most serious adverse reaction was meningococcal sepsis.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Depression, anxiety, insomnia, sleep disorder, abnormal dreams, mood swings<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Proteinuria, urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematuria, dysuria, spontaneous penile erection, menstrual disorder</p>
<p><b>Rare</b> (0.01% to 0.1%): Genitourinary tract gonococcal infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (15%), pruritus (10%)</p>
<p><b>Common</b> (1% to 10%): Alopecia</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria, dermatitis, erythema, petechiae, skin depigmentation, hyperhidrosis, dry skin<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Grave's disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Jaundice<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactic reaction</p>
<p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site paresthesia, infusion site pain, extravasation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (18%)</p>
<p><b>Common</b> (1% to 10%): Decreased appetite</p>
<p><b>Uncommon</b> (0.1% to 1%): Anorexia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, conjunctival irritation<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Malignant melanoma, myelodysplastic syndrome<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Edema, chest discomfort, pyrexia, chills, fatigue, asthenia, influenza like illness</p>
<p><b>Uncommon</b> (0.1% to 1%): Tinnitus, vertigo, feeling hot<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Renal impairment<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Soliris (eculizumab)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Soliris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Myasthenia Gravis</li>
<li>Paroxysmal Nocturnal Hemoglobinuria</li>
<li>Hemolytic Uremic Syndrome</li>
<li>Neuromyelitis Optica</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to eculizumab: intravenous solution</i></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Meningococcal sepsis, aspergillus infection, arthritis bacterial, oral herpes, viral infection</p><p><b>Uncommon</b> (0.1% to 1%): Meningococcal meningitis, Neisseria infection, sepsis, septic shock, fungal infection, Haemophilus influenza infection, abscess, cellulitis, influenza, cystitis, gingival infection, impetigo, tooth infection</p><p><b>Rare</b> (0.01% to 0.1%): Aspergillus infection, bacterial arthritis, impetigo<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, nasopharyngitis, bronchitis, dyspnea, cough, nasal congestion, pharyngolaryngeal pain, rhinorrhea, pneumonia</p><p><b>Uncommon</b> (0.1% to 1%): Lower respiratory tract infection, sinusitis, epistaxis, throat irritation<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (15%), arthralgia (17%)</p><p><b>Common</b> (1% to 10%): Myalgia, muscle spasms, bone pain, neck pain, pain in extremity</p><p><b>Uncommon</b> (0.1% to 1%): Trismus, joint swelling<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, vomiting, nausea, abdominal pain, constipation, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Gastrointestinal infection, peritonitis, gastroesophageal reflux disease, abdominal distension, gingival pain</p><p><b>Rare</b> (0.01% to 0.1%): Gingivitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Thrombocytopenia, leukopenia, anemia, hemolysis</p><p><b>Uncommon</b> (0.1% to 1%): Coagulopathy, red blood cell agglutination, abnormal clotting factor, anemia, lymphopenia, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased, hematocrit decreased, hemoglobin decreased, thrombocytopenia, lymphopenia</p><p><b>Rare</b> (0.01% to 0.1%): Hemolysis, abnormal clotting factor, red blood cell agglutination, coagulopathy<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (33%), hypotension (17%)</p><p><b>Uncommon</b> (0.1% to 1%): Palpitation, accelerated hypertension, hematoma, hot flush, vein disorder<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (41%)</p><p><b>Common</b> (1% to 10%): Dizziness, dysgeusia</p><p><b>Uncommon</b> (0.1% to 1%): Syncope, tremor, paresthesia<sup>[Ref]</sup></p><h3>General</h3><p>The most common adverse reaction was headache (occurred mostly in the initial phase) and the most serious adverse reaction was meningococcal sepsis.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Depression, anxiety, insomnia, sleep disorder, abnormal dreams, mood swings<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Proteinuria, urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Hematuria, dysuria, spontaneous penile erection, menstrual disorder</p><p><b>Rare</b> (0.01% to 0.1%): Genitourinary tract gonococcal infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (15%), pruritus (10%)</p><p><b>Common</b> (1% to 10%): Alopecia</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria, dermatitis, erythema, petechiae, skin depigmentation, hyperhidrosis, dry skin<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Uncommon</b> (0.1% to 1%): Grave's disease<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Jaundice<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Anaphylactic reaction</p><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Infusion site paresthesia, infusion site pain, extravasation<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (18%)</p><p><b>Common</b> (1% to 10%): Decreased appetite</p><p><b>Uncommon</b> (0.1% to 1%): Anorexia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, conjunctival irritation<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Malignant melanoma, myelodysplastic syndrome<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Edema, chest discomfort, pyrexia, chills, fatigue, asthenia, influenza like illness</p><p><b>Uncommon</b> (0.1% to 1%): Tinnitus, vertigo, feeling hot<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Renal impairment<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc, Cheshire, CT. </p><h2>More about Soliris (eculizumab)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>2 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (2)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Soliris &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Myasthenia Gravis</li>
<li>Paroxysmal Nocturnal Hemoglobinuria</li>
<li>Hemolytic Uremic Syndrome</li>
<li>Neuromyelitis Optica</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>